12,372 trials
Acute Lung Injury
Primary: All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge — 15; 6 Participants
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) by Investigator Assessment — NA; 11.1 months — p=<0.0001
Diabetes · Diabetes Mellitus, Type 2
Primary: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke — 6.6; 8.9 percentage of…
Prostate Cancer · Castration Resistant Prostate Cancer · Pain
Primary: Overall Survival (OS) — 11.0; 9.8 months — p=0.213
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.2; 95.4; 96.0 percentage of participants
Esophageal Cancer
Primary: Overall Survival (24-month Rate Reported) — 44.9; 44.0 percentage of participants — p=0.47
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) — 77.9 Percentage of participants
Rhinitis, Vasomotor
Primary: Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS) — -1.71; -2.05 Score on scale — p=0.050
Respiratory Syncytial Virus (RSV)
Primary: Percentage of Participants With RSV Hospitalization — 0.0 percentage of participants
Moderate to Severe Nail Psoriasis
Primary: Percentage Change From Baseline in Nail Psoriasis Severity Index (NAPSI) After 16 Weeks of Treatment — -38.4; -46.1; -11.7 percent change — p=<0.0001
Hepatitis C, Chronic
Primary: Number of Full Analysis Set Participants Who Received HCV Anti-viral Therapy With Sustained Virological Response (SVR) — 4; 4 participants — p=0.01
Hyperlipidemia
Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24 — -16.70; -54.50 percent change — p=<0.0001
COPD · Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 — 0.0847; 0.0921; 0.0111 liters — p=0.0002
Sporadic Inclusion Body Myositis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths. — 48; 50; 44; 49 Participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAE) — 430; 312 participants